|
Primary peritoneal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.
|
21855113 |
2012 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
SCARA3 messenger RNA (mRNA) expression was analyzed in 127 effusions (103 ovarian/peritoneal/fallopian tube carcinomas, 9 breast carcinomas, 15 malignant mesotheliomas [MM]), and 30 solid primary OCs.
|
21855113 |
2012 |
|
Mesothelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SCARA3 messenger RNA (mRNA) expression was analyzed in 127 effusions (103 ovarian/peritoneal/fallopian tube carcinomas, 9 breast carcinomas, 15 malignant mesotheliomas [MM]), and 30 solid primary OCs.
|
21855113 |
2012 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
SCARA3 levels in effusions and primary carcinomas were unrelated to patient age, tumor grade, FIGO stage, residual tumor volume after surgery, response to chemotherapy, or survival (P > .05 for all).
|
21855113 |
2012 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
SCARA3 levels in effusions and primary carcinomas were unrelated to patient age, tumor grade, FIGO stage, residual tumor volume after surgery, response to chemotherapy, or survival (P > .05 for all).
|
21855113 |
2012 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
CSR1 suppresses tumor growth and metastasis of human hepatocellular carcinoma via inhibition of HPIP.
|
28975986 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CSR1 suppresses tumor growth and metastasis of human hepatocellular carcinoma via inhibition of HPIP.
|
28975986 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
A clustering enrichment regime using the CSR genes and two independent breast tumor data-sets was used to identify a 42-gene aggressive tumor gene signature.
|
20152043 |
2010 |
|
Thymoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
At quantitative assessment, both the radiodensity and CSR were significantly higher for thymoma compared with nonthymoma groups (<i>P</i> < .001).
|
31331197 |
2020 |
|
Cheyne-Stokes Respiration
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Background The contribution of the lung or the plant gain ( PG ; ie, change in blood gases per unit change in ventilation) to Cheyne-Stokes respiration ( CSR ) in heart failure has only been hypothesized by mathematical models, but never been directly evaluated.
|
31237174 |
2019 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene whose expression was frequently down-regulated in prostate cancer.
|
25956032 |
2015 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene whose expression was frequently down-regulated in prostate cancer.
|
25956032 |
2015 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene whose expression was frequently down-regulated in prostate cancer.
|
25956032 |
2015 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene that plays an important role in regulating cell death.
|
27148859 |
2017 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene that was frequently down-regulated in prostate cancer.
|
28975986 |
2017 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cellular stress response 1 (CSR1) is a tumor suppressor gene that was frequently down-regulated in prostate cancer.
|
28975986 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Cellular Stress Response 1 (CSR1) is a tumor suppressor gene and frequently deleted in prostate cancers.
|
29705808 |
2018 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cellular Stress Response 1 (CSR1) is a tumor suppressor gene and frequently deleted in prostate cancers.
|
29705808 |
2018 |
|
Heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Conclusions PG is a powerful contributor of CSR and should be evaluated together with the CG and circulation time to individualize treatments aimed at stabilizing breathing in heart failure.
|
31237174 |
2019 |
|
Congestive heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Conclusions PG is a powerful contributor of CSR and should be evaluated together with the CG and circulation time to individualize treatments aimed at stabilizing breathing in heart failure.
|
31237174 |
2019 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
CSR1 suppresses tumor growth and metastasis of prostate cancer.
|
16436673 |
2006 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of CSR1 in PC3 cell xenografts produced a dramatic reduction (>8-fold) in tumor size, rate of invasion (0 versus 31%), and mortality (13 versus 100%).
|
16436673 |
2006 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
For the first time we demonstrated that CSR1 inhibited HCC cell proliferation, migration and invasion through inactivation of HPIP and its downstream PI3K/AKT signaling pathway and suggested CSR1 as a potential therapy target for HCC treatment.
|
28975986 |
2017 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CSR1 in prostate cancer cell lines DU145 and PC3 resulted in a two- to threefold decrease in colony formation and a 10-fold reduction in anchorage-independent growth.
|
16436673 |
2006 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CSR1 in prostate cancer cell lines DU145 and PC3 resulted in a two- to threefold decrease in colony formation and a 10-fold reduction in anchorage-independent growth.
|
16436673 |
2006 |